Dr Giorgio Barbarini

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background: The differential tolerability profile of various interferon (IFN)-α preparations used in combination with ribavirin for the treatment of chronic hepatitis C needs to be elucidated. Approximately 8% of patients receiving recombinant IFNα-2b plus ribavirin discontinue treatment because of adverse events. Human leucocyte IFNα is deemed to have a(More)
  • 1